Show results for
Refine by
Inflammatory Lung Disease Suppliers & Manufacturers
7 companies found
Technologybased inParis, FRANCE
Abivax develops innovative treatments modulating the body’s natural immune system machinery to treat patients with chronic inflammatory diseases, viral infections and cancer. As a clinical-stage company, Abivax leverages its immune enhancing and ...
Technologybased inCambridge, MASSACHUSETTS (USA)
Iterative Health is pioneering the use of artificial intelligence-based precision medicine in gastroenterology (GI), with the aim of helping to optimize clinical trials investigating treatment of inflammatory bowel disease (IBD) and improving the ...
Technologybased inSaint Kevin`s, IRELAND
At Horizon, we believe science and compassion must work together to transform lives. Our mission to deliver medicines for rare, autoimmune and severe inflammatory diseases and provide compassionate support comes from our strong and simple philosophy ...
Technologybased inSouth San Francisco, CALIFORNIA (USA)
Superfluid’s platform technology is applicable to a wide variety of diseases. We are currently focused on Alzheimer’s Disease, where there are urgent medical needs. This minimally invasive approach eliminates the need for spinal taps and ...
Technologybased inBundoora, AUSTRALIA
AdAlta is an innovative, clinical stage biotech company developing a unique range of new drug treatments. AdAlta has pioneered a technology that mimics the shape and stability of a crucial antigen-binding domain, discovered initially in sharks and ...
Technologybased inBasel, SWITZERLAND
Aurealis Therapeutics, a Swiss-Finnish private biopharmaceutical company, is now entering the clinical trial phase with its patented three-in-one combination product AUP-16 for chronic non-healing wounds and other regenerative diseases. The ...
Technologybased inRockville, MARYLAND (USA)
Since the treatment of our first oncology patient in 2015, AbelZeta has been able to build best-in-class and best-in-disease potential pipeline, leading to the licensing of two CD20-directed autologous CAR-Ts to Janssen Biotech in 2023. Our goal is ...